Edition:
India

Aceto Corp (ACET.OQ)

ACET.OQ on NASDAQ Stock Exchange Global Select Market

2.60USD
1:30am IST
Change (% chg)

$0.11 (+4.42%)
Prev Close
$2.49
Open
$2.52
Day's High
$2.62
Day's Low
$2.46
Volume
126,156
Avg. Vol
160,146
52-wk High
$17.10
52-wk Low
$2.22

Latest Key Developments (Source: Significant Developments)

Aceto-With DOJ’S Ongoing Investigation In Marketing, Pricing Practices In Generic Pharma Industry, Co Got Subpoena From U.S. DOJ Antitrust Division
Monday, 23 Apr 2018 

April 23 (Reuters) - Aceto Corp ::ACETO-WITH DOJ’S ONGOING INVESTIGATION IN MARKETING, PRICING PRACTICES IN GENERIC PHARMACEUTICAL INDUSTRY, CO GOT SUBPOENA FROM U.S. DOJ ANTITRUST DIVISION.ACETO CORP SAYS COMPANY IS CURRENTLY PREPARING ITS RESPONSE TO THE SUBPOENA - SEC FILING.  Full Article

Aceto Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25Mg, 50Mg And 100Mg
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES ATENOLOL TABLETS, 25MG, 50MG AND 100MG.ACETO - UNIT LAUNCHED ATENOLOL TABLETS, 25MG, 50MG AND 100MG, GENERIC VERSION OF TENORMIN FROM ALVOGEN MALTA OPERATIONS.  Full Article

Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES EFAVIRENZ CAPSULES, 50MG AND 200MG.SAYS UNIT ‍LAUNCHED GENERIC FOR EFAVIRENZ CAPSULES, AN FDA-APPROVED GENERIC VERSION OF REFERENCE LISTED DRUG SUSTIVA FROM BRISTOL MYERS SQUIBB​.  Full Article

Aceto reports fiscal 2018 first quarter results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Aceto Corp :Aceto reports fiscal 2018 first quarter results.Q1 adjusted non-GAAP earnings per share $0.30.Q1 earnings per share $0.01.Q1 sales $185.3 million versus I/B/E/S view $190.6 million.Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S.Sees FY 2018 non-GAAP earnings per share $1.05 to $1.15.Aceto Corp sees ‍fiscal 2018 total revenues to increase approximately 15% to 20%​.Aceto Corp sees ‍fiscal 2018 reported diluted GAAP earnings per share between $0.23 and $0.33​.  Full Article

Aceto corp CFO Douglas Roth notifies co he will retire effective March 31, 2018​
Saturday, 28 Oct 2017 

Oct 27 (Reuters) - Aceto Corp ::Says on October 26, Douglas Roth, Chief Financial Officer of Aceto Corporation notified company that he will retire effective March 31, 2018​.  Full Article

ACETO appoints William Kennally, III president and CEO
Thursday, 28 Sep 2017 

Sept 27 (Reuters) - ACETO Corp :ACETO appoints William Kennally, III president and CEO.ACETO Corp - ‍Salvatore Guccione, ACETO's chief executive officer has stepped down from all positions with ACETO​.  Full Article

Verdezyne signs distribution agreement with Aceto Corp
Wednesday, 5 Oct 2016 

Aceto Corp : BIOLON DDDA will be produced by verdezyne and will be distributed in United States Of America by Aceto .Verdezyne signs distribution agreement with Aceto Corporation.  Full Article

Aceto reports Q4 EPS $0.23
Friday, 26 Aug 2016 

Aceto Corp : Aceto reports fiscal 2016 fourth quarter and record full year results . Q4 adjusted non-gaap earnings per share $0.35 . Q4 earnings per share $0.23 . Q4 earnings per share view $0.39 -- Thomson Reuters I/B/E/S . Qtrly net sales of $135.4 million versus $146.6 million, a 7.6% decrease . "regarding 2017, we are expecting to grow both sales and net income" . For fiscal 2017, expecting both sales and non-gaap adjusted earnings per share to grow in mid-single digit percentage range . For fiscal 2017 expecting gaap earnings per share growing at a somewhat slower rate .Q4 revenue view $146.7 million -- Thomson Reuters I/B/E/S.  Full Article

Aceto's board increases qtrly dividend by 8.3 pct to $0.065/share
Friday, 26 Aug 2016 

Aceto Corp : Aceto board of directors increases quarterly cash dividend by 8.3 pct .Board of directors has increased its regular quarterly dividend to $0.065 per common share.  Full Article

BRIEF-Aceto To Appeal U.S. Government Ruling Regarding Certain Lucid Pharma Contracts

* ACETO TO APPEAL U.S. GOVERNMENT RULING REGARDING CERTAIN LUCID PHARMA CONTRACTS